Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptorpositive breast cancers

Seho Park, Eunjin Koh, Ja Seung Koo, Seung Il Kim, Byeong Woo Park, Kyung Sup Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The present study aimed to examine the associations between androgen receptor (AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features and survival according to both biomarker status in estrogen receptor (ER)-positive breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 demonstrated AR-overexpressing cell lines decreased in cell proliferation through downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted in a significantly reduced cell viability. Patients with immunohistochemically AR(- )/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 proliferation, therefore, significantly worse survival in ER-positive disease. AR and FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like subtype and worse disease-free survival in ER-positive cancers of public gene dataset, similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently validated patients with both low AR/FOXA1 tumor were significantly associated with worse relapse-free survival in ER-positive cancers. This study suggests that distinctive clinicopathological features according to AR and FOXA1 are determined and a lack of both biomarkers is an independent poor prognostic factor in ER-positive tumors.

Original languageEnglish
Pages (from-to)82940-82955
Number of pages16
JournalOncotarget
Volume8
Issue number47
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Androgen Receptors
Estrogen Receptors
Estrogens
Breast Neoplasms
Neoplasms
Survival
Biomarkers
Neoplasm Genes
Kaplan-Meier Estimate
Genomics
Disease-Free Survival
Cell Survival
Cohort Studies
Down-Regulation
Cell Proliferation
Neoplasm Metastasis
Recurrence
Cell Line
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{057752cf498c4c5b9212ce49aa61aed3,
title = "Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptorpositive breast cancers",
abstract = "The present study aimed to examine the associations between androgen receptor (AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features and survival according to both biomarker status in estrogen receptor (ER)-positive breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 demonstrated AR-overexpressing cell lines decreased in cell proliferation through downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted in a significantly reduced cell viability. Patients with immunohistochemically AR(- )/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 proliferation, therefore, significantly worse survival in ER-positive disease. AR and FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like subtype and worse disease-free survival in ER-positive cancers of public gene dataset, similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently validated patients with both low AR/FOXA1 tumor were significantly associated with worse relapse-free survival in ER-positive cancers. This study suggests that distinctive clinicopathological features according to AR and FOXA1 are determined and a lack of both biomarkers is an independent poor prognostic factor in ER-positive tumors.",
author = "Seho Park and Eunjin Koh and Koo, {Ja Seung} and Kim, {Seung Il} and Park, {Byeong Woo} and Kim, {Kyung Sup}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20937",
language = "English",
volume = "8",
pages = "82940--82955",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "47",

}

Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptorpositive breast cancers. / Park, Seho; Koh, Eunjin; Koo, Ja Seung; Kim, Seung Il; Park, Byeong Woo; Kim, Kyung Sup.

In: Oncotarget, Vol. 8, No. 47, 01.01.2017, p. 82940-82955.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptorpositive breast cancers

AU - Park, Seho

AU - Koh, Eunjin

AU - Koo, Ja Seung

AU - Kim, Seung Il

AU - Park, Byeong Woo

AU - Kim, Kyung Sup

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The present study aimed to examine the associations between androgen receptor (AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features and survival according to both biomarker status in estrogen receptor (ER)-positive breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 demonstrated AR-overexpressing cell lines decreased in cell proliferation through downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted in a significantly reduced cell viability. Patients with immunohistochemically AR(- )/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 proliferation, therefore, significantly worse survival in ER-positive disease. AR and FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like subtype and worse disease-free survival in ER-positive cancers of public gene dataset, similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently validated patients with both low AR/FOXA1 tumor were significantly associated with worse relapse-free survival in ER-positive cancers. This study suggests that distinctive clinicopathological features according to AR and FOXA1 are determined and a lack of both biomarkers is an independent poor prognostic factor in ER-positive tumors.

AB - The present study aimed to examine the associations between androgen receptor (AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features and survival according to both biomarker status in estrogen receptor (ER)-positive breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 demonstrated AR-overexpressing cell lines decreased in cell proliferation through downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted in a significantly reduced cell viability. Patients with immunohistochemically AR(- )/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 proliferation, therefore, significantly worse survival in ER-positive disease. AR and FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like subtype and worse disease-free survival in ER-positive cancers of public gene dataset, similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently validated patients with both low AR/FOXA1 tumor were significantly associated with worse relapse-free survival in ER-positive cancers. This study suggests that distinctive clinicopathological features according to AR and FOXA1 are determined and a lack of both biomarkers is an independent poor prognostic factor in ER-positive tumors.

UR - http://www.scopus.com/inward/record.url?scp=85030857281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030857281&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20937

DO - 10.18632/oncotarget.20937

M3 - Article

AN - SCOPUS:85030857281

VL - 8

SP - 82940

EP - 82955

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 47

ER -